Download Your Copy of the Agenda to Explore
40+
World-class speakers from industry pioneers including Bristol Myers Squibb, AbbVie, Otsuka, Johnson & Johnson, Biogen, Boehringer Ingelheim and more
15+
Hours of face-to-face networking with large pharma, innovative biotech, venture capitalists, academics, and solution providers
6
Hours of workshop content deciphering psychedelic clinical challenges with MindMed, Compass, and Cybin, and bridging the translational gap with Kinoxis and Evexcia
25+
Hours of data-driven presentations spanning depression, schizophrenia, autism, addiction, PTSD, agitation, bipolar and anxiety drug development
Having trouble downloading the brochure? Let us know here and we’ll email it to you instead
Scientific Poster Session
Discover additional new and exclusive unpublished data at the Scientific Poster Session
A Snapshot of Last Year's Submissions:
Evaluating targeted therapies in preclinical models using EEG
Semi-systematic series of indolethylamine derivatives reveals that hallucination is not required for positive behavioural outcomes in mice
OT-003 improves cognition, negative symptoms and brain pathology in rat schizophrenia models
A dose-optimization study of single dose of MM120 (lysergide) in generalized anxiety disorder
